Interest of Combining Speech Therapy With a Non-invasive Brain Stimulation (tDCS) for the Aphasic Patient

NCT ID: NCT02612753

Last Updated: 2016-07-26

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Clinical Phase

NA

Total Enrollment

24 participants

Study Classification

INTERVENTIONAL

Study Start Date

2015-11-30

Study Completion Date

2018-10-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Aphasia is a frequent symptom after a left hemisphere stroke. It has serious impacts on social, family and professional lives. Aphasic patients need to be rehabilitated. To date, no pharmacological treatment being available only speech and language therapy (SLT) can improve patients, but its efficiency is moderate. Several studies have investigated the link between the recovery of language and neural reorganization. tDCs, a noninvasive technology for modulating neural excitability, could potentiate the effects of the SLT. About 25 studies in literature have described beneficial effects of tDCs coupled with SLT on aphasic patients. However to the investigator knowledge the feasibility of tDCs and speech therapy in clinical pathways has never been investigated. That is why the investigator propose to study in real care conditions how SLT proves more efficient on the recovery of language in a discursive assessment when coupled with active stimulation than with placebo stimulation.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

This is a multicenter, cross-over, randomized, controlled and double blind study. 24 patients will be included between November 2015 and November 2017.

During each session of speech and language treatment, aphasics will receive a weak 2 milli amperes (electric) current delivered by a tDCs device for 20 minutes. The stimulation will be either active or placebo. Each stage of the cross over will last three weeks. Patients will be administered the usual number of SLT sessions, no particular therapy being imposed. To evaluate the long-time effects of the therapy, three follow-up measures will be proposed.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Aphasia

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

CROSSOVER

Primary Study Purpose

TREATMENT

Blinding Strategy

DOUBLE

Participants Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Aphasics Patients

Patients which have difficulties to speak. Improvement of language for aphasics patients.

Group Type EXPERIMENTAL

improvement of language for aphasics patients

Intervention Type PROCEDURE

Aphasics patients receive active stimulation during SLT

tDCs

Intervention Type DEVICE

Aphasics Patients control

Patients which have difficulties to speak will receive Sham tDCS +SLT for aphasics patients control

Group Type SHAM_COMPARATOR

improvement of language for aphasics patients

Intervention Type PROCEDURE

Aphasics patients receive active stimulation during SLT

Sham tDCS

Intervention Type DEVICE

Aphasics patients control receive sham stimulation during SLT

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

improvement of language for aphasics patients

Aphasics patients receive active stimulation during SLT

Intervention Type PROCEDURE

Sham tDCS

Aphasics patients control receive sham stimulation during SLT

Intervention Type DEVICE

tDCs

Intervention Type DEVICE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Patient more than 18 years
* Aphasic Following a brain injury identified by MRI.
* Present a aphasia severity score\> 1 on the Boston Diagnostic Aphasia Examination (BDAE) severity scale.
* No Post stroke delay is retained but the patient should be stable from a medical point of view.
* Master Of the French language in spoken and written
* Affiliated to a social security
* Patient Who signed the informed consent

Exclusion Criteria

* Other previous neurological pathologies
* epileptic crisis during the previous 2 months
* Patient denies
* Presence of a cranial flap
* intracerebral metal hardware Presence
* Patient under guardianship
* Patient unable to understand the study
* Patient subject to an exclusion period for another search.
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Fondation Paul Bennetot

OTHER

Sponsor Role collaborator

Fondation Garches

OTHER

Sponsor Role collaborator

Centre d'Investigation Clinique et Technologique 805

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

AZOUVI

MDPHD

Responsibility Role PRINCIPAL_INVESTIGATOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Philippe AZOUVI, MDPHD

Role: PRINCIPAL_INVESTIGATOR

Hopital RAYMOND POINCARE

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Hopital Raymond Poincare

Garches, Garches, France

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

France

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Philippe AZOUVI, MDPHD

Role: CONTACT

0033147107074

Nicolas ROCHE, MD

Role: CONTACT

0033147107900

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

PHILIPPE AZOUVI, MDPHD

Role: primary

0033147107074

SANDRA POTTIER, CRA

Role: backup

0033147104469

References

Explore related publications, articles, or registry entries linked to this study.

Greener J, Enderby P, Whurr R. Speech and language therapy for aphasia following stroke. Cochrane Database Syst Rev. 2000;(2):CD000425. doi: 10.1002/14651858.CD000425.

Reference Type RESULT
PMID: 10796360 (View on PubMed)

Nitsche MA, Paulus W. Excitability changes induced in the human motor cortex by weak transcranial direct current stimulation. J Physiol. 2000 Sep 15;527 Pt 3(Pt 3):633-9. doi: 10.1111/j.1469-7793.2000.t01-1-00633.x.

Reference Type RESULT
PMID: 10990547 (View on PubMed)

Elsner B, Kugler J, Pohl M, Mehrholz J. Transcranial direct current stimulation (tDCS) for improving aphasia in patients with aphasia after stroke. Cochrane Database Syst Rev. 2015 May 1;(5):CD009760. doi: 10.1002/14651858.CD009760.pub3.

Reference Type RESULT
PMID: 25929694 (View on PubMed)

Robey RR. A meta-analysis of clinical outcomes in the treatment of aphasia. J Speech Lang Hear Res. 1998 Feb;41(1):172-87. doi: 10.1044/jslhr.4101.172.

Reference Type RESULT
PMID: 9493743 (View on PubMed)

Klippi A, Sellman J, Heikkinen P, Laine M. Current clinical practices in Aphasia Therapy in Finland: challenges in moving towards national best practice. Folia Phoniatr Logop. 2012;64(4):169-78. doi: 10.1159/000341106. Epub 2012 Oct 25.

Reference Type RESULT
PMID: 23108446 (View on PubMed)

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

2014-A01773-44

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Brain Stimulation and Aphasia Treatment
NCT01686373 COMPLETED PHASE2
tDCS to Treat Subacute Aphasia
NCT04048668 WITHDRAWN NA